Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

SARS-CoV Spike antibody

This anti-SARS-CoV Spike antibody is a Mouse Monoclonal antibody detecting SARS-CoV Spike in ELISA, WB, IF and IC. Suitable for SARS Coronavirus (SARS-CoV). This Primary Antibody has been cited in 5+ publications.
Catalog No. ABIN2452119

Quick Overview for SARS-CoV Spike antibody (ABIN2452119)

Target

See all SARS-CoV Spike (SARS-CoV S) Antibodies
SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

Reactivity

  • 40
  • 16
  • 1
SARS Coronavirus (SARS-CoV)

Host

  • 38
  • 2
  • 1
Mouse

Clonality

  • 38
  • 3
Monoclonal

Conjugate

  • 20
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This SARS-CoV Spike antibody is un-conjugated

Application

  • 25
  • 18
  • 5
  • 3
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
ELISA, Western Blotting (WB), Immunofluorescence (IF), Immunochromatography (IC)

Clone

3A2
  • Characteristics

    Monoclonal antibody 3A2 recognizes the spike protein consisting of 1181 amino acids, which migrates at 200 kDa position on SDS-PAGE due to its glyco-chains.

    Purification

    Purified

    Sterility

    Sterile filtered

    Isotype

    IgG2b kappa
  • Application Notes

    1) Western blotting: 0. 1~0. 3 g/mL
    2) Immunofluoresece staining (IHC)
    3) ELISA Isoform: IgG2b (kappa)

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    1 mg/mL

    Buffer

    PBS, 50 % glycerol

    Preservative

    Azide free

    Storage

    -20 °C/-80 °C

    Storage Comment

    -20 C (For long term storage: -80 C)
  • Jin, Nesbitt, Yang, Chen, Horowitz, Jones, Vandergaast, Carey, Reiter, Russell, Kyratsous, Hooper, Hamilton, Ferreira, Deng, Straus, Baras, Hillyer, Luchsinger: "Seroprevalence of anti-SARS-CoV-2 antibodies in a cohort of New York City metro blood donors using multiple SARS-CoV-2 serological assays: Implications for controlling the epidemic and "Reopening"." in: PloS one, Vol. 16, Issue 4, pp. e0250319, (2021) (PubMed).

    Nesbitt, Jin, Hogan, Yang, Chen, Chan, Simon, Vargas, King, Huard, Bandy, Hillyer, Luchsinger: "Low Seroprevalence of SARS-CoV-2 in Rhode Island blood donors during may 2020 as determined using multiple serological assay formats." in: BMC infectious diseases, Vol. 21, Issue 1, pp. 871, (2021) (PubMed).

    Luchsinger, Ransegnola, Jin, Muecksch, Weisblum, Bao, George, Rodriguez, Tricoche, Schmidt, Gao, Jawahar, Pal, Schnall, Zhang, Strauss, Yazdanbakhsh, Hillyer, Bieniasz, Hatziioannou: "Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients." in: Journal of clinical microbiology, (2020) (PubMed).

    Satija, Lal: "The molecular biology of SARS coronavirus." in: Annals of the New York Academy of Sciences, Vol. 1102, pp. 26-38, (2007) (PubMed).

    Yamate, Yamashita, Goto, Tsuji, Li, Warachit, Yunoki, Ikuta: "Establishment of Vero E6 cell clones persistently infected with severe acute respiratory syndrome coronavirus." in: Microbes and infection / Institut Pasteur, Vol. 7, Issue 15, pp. 1530-40, (2005) (PubMed).

  • Target

    SARS-CoV Spike (SARS-CoV S) (SARS-Coronavirus Spike Protein (SARS-CoV S))

    Alternative Name

    SARS-CoV Spike

    Target Type

    Viral Protein

    Background

    A novel type of coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Spike glycoprotein is essential for the infection and directly binds to the virus receptor, ACE2 (Angiotensin-Converting Enzyme 2). Hybridoma 3A2 has been isolated by injecting mouse with SARS virus and as the clone which produces antibody that specifically reacts with the virus-infected cell, in the laboratory of Prof. K. Ikuta of Osaka University.
You are here:
Chat with us!